Toxicity-attenuated mesoporous silica Schiff-base bonded anticancer drug complexes for chemotherapy of drug resistant cancer

  • Colloids Surf B Biointerfaces. 2021 Sep:205:111839. doi: 10.1016/j.colsurfb.2021.111839.
Ling Cai  1 ,  Ping Zhu  2 ,  Fei Huan  3 ,  Jun Wang  2 ,  Liuzhu Zhou  2 ,  Huijun Jiang  4 ,  Minghui Ji  5 ,  Jin Chen  6
Affiliations
  • 1. School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 211189, China; Center for Global Health, The Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, 211166, Nanjing, China.
  • 2. Center for Global Health, The Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, 211166, Nanjing, China.
  • 3. Safety Assessment and Research Center for Drug, Pesticide and Veterinary Drug of Jiangsu Province, Nanjing Medical University, 211166, Nanjing, China.
  • 4. School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
  • 5. School of Nursing, Nanjing Medical University, Nanjing, 211166, China.
  • 6. School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 211189, China; Center for Global Health, The Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, 211166, Nanjing, China; Jiangsu Province Engineering Research Center of Antibody Drug, Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China. Electronic address: [email protected].
PMID: 34022700 DOI: 10.1016/j.colsurfb.2021.111839
Abstract

Multidrug resistance (MDR), evoked by improper chemotherapeutic practices, poses a serious threat to public health, which leads to increased medical burdens and weakened curative effects. Taking advantage of the enhanced pharmaceutical effect of Schiff base compounds, an aldehyde-modified mesoporous silica SBA-15 (CHO-SBA-15)-bonded Anticancer drug combined with doxorubicin hydrochloride (DOX) was synthesized via a Schiff base reaction. Due to the acid-sensitive imine bonds formed between CHO-SBA-15 and DOX, the as-prepared nanocomposites exhibited pH-responsive drug releasing behaviours, resulting in a more enhanced cytotoxic effect on DOX-resistant tumour cells than that of free drugs. Notably, the in vivo studies indicated that mice treated with CHO-SBA-15/DOX composites evidently showed more attenuated systemic toxicity than the free drug molecules. The siliceous mesopore Schiff base-bonded Anticancer drug nanocomposite, with minimal chemical modifications, provides a simplified yet efficient therapeutic nanoplatform to deal with drug-resistant Cancer.

Keywords
Drug delivery; Drug resistant cancer; Mesoporous silica; Schiff base.
Products
Inhibitors & Agonists
Other Products